BioTuesdays

Profound Medical closes upsized bought deal financing

Profound Medical

Profound Medical (TSXV:PRN) closed a previously announced bought deal financing for gross proceeds of $34.5-million, including the exercise of the underwriters’ over-allotment option.

Net proceeds are expected to be used to advance Profound’s TACT pivotal clinical trial; ongoing expansion of infrastructure to execute on global sales and marketing plans for Profound’s TULSA-PRO and Sonalleve systems; support ongoing R&D and acquisitions in order to expand the applications of Profound’s current and future platform; and for general corporate purposes.

The offering was conducted by a syndicate of underwriters led by Canaccord Genuity and including Paradigm Capital, CIBC World Markets, Beacon Securities, Echelon Wealth Partners and Mackie Research Capital.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.